🩸 Red Blood Journal
Report #1830
The Investigation Medicine Does Not Want to Have
A Special Announcement About the Upcoming Multipart Report
There are questions society is encouraged to ask.
And then there are questions that immediately cause institutions to raise their shields.
Why do certain dangerous products remain available despite causing thousands of injuries, illnesses and deaths—while an extraordinarily effective medicine can disappear because of a statistically rare risk?
Why may an adult legally purchase alcohol, cigarettes, Roundup or a motorcycle, yet be denied access to a cold medicine that once provided remarkable relief?
Why are doctors told they may prescribe approved medicines off-label, while some physicians who exercised that authority during COVID faced investigations, professional sanctions, restricted licenses and destroyed reputations?
Why was human ivermectin repeatedly described as “horse medicine” when it had been prescribed to human patients by licensed physicians?
Why were inexpensive treatments publicly dismissed before governments completed the large, immediate and independent trials that could have resolved the controversy?
Why do institutions tolerate enormous risks when powerful industries depend upon a product—but suddenly become unwilling to tolerate even the smallest risk when an inexpensive and effective medicine stands alone?
These questions began with a memory.
The Medicine That Made a Cold Disappear
There was once an over-the-counter medicine called Comtrex.
Those who used its original formula may remember something unusual about it.
It worked.
A person could feel a cold beginning, take the recommended capsules and experience relief across nearly every major symptom. Congestion opened. Coughing settled. Sneezing stopped. Fever and body aches faded.
It did not require an entire shelf of specialized products.
It was convenient.
It was comprehensive.
And then, almost without public discussion, the original formula disappeared.
The official explanation involved an ingredient associated with an extremely rare risk of hemorrhagic stroke.
At first, that explanation appears reasonable.
But an investigator must continue asking questions.
How rare was the risk?
Was it conclusively demonstrated among ordinary cold-medicine users?
Why was the ingredient not restricted to prescription or pharmacist-controlled access?
Why were informed adults denied the opportunity to accept that risk?
And why are substances connected to far greater numbers of cancers, injuries and deaths still legally sold every day?
That is where the Comtrex story stops being a story about cold medicine.
It becomes an investigation into who controls healing.
The Contradiction on the Store Shelf
Walk through a major home-improvement store and products carrying the Roundup name remain visible.
Glyphosate—the ingredient historically identified with Roundup—has been associated in litigation and scientific debate with Non-Hodgkin lymphoma. Bayer and Monsanto have faced enormous verdicts, settlements and approximately 177,000 claims.
Yet glyphosate remains deeply embedded in industrial agriculture.
Why?
Because it is materially important.
It supports a massive agricultural system, powerful corporations, commercial supply chains and financial interests extending around the world.
Now compare that response with Comtrex.
An enormously useful cold medicine lost its defining ingredient over a rare risk, while products surrounded by far greater allegations of human harm remained protected by warnings, directions and regulatory approval.
The difference may not be danger.
The difference may be material power.
When Doctors Require Permission to Practice Medicine
During COVID, the public was repeatedly told that physicians remained free to prescribe approved medicines off-label.
Technically, that was true.
On the ground, the reality was different.
Physicians who prescribed or promoted ivermectin faced complaints, investigations, hospital sanctions, license restrictions, fines and loss of professional certification.
Pharmacies refused valid prescriptions.
Hospitals prevented outside physicians from treating patients.
Media organizations portrayed a recognized human medicine as a veterinary drug.
Patients and doctors learned an unmistakable lesson:
A treatment does not need to be prohibited by law when fear can make prescribing it professionally dangerous.
That is not medical freedom.
It is medicine practiced under institutional permission.
Beyond Fauci
This investigation will not reduce the entire COVID era to one public official.
Dr. Anthony Fauci became the face of the system, but the system extended far beyond him.
It included:
Government research agencies
Pharmaceutical corporations
Medical licensing boards
Hospital administrators
Professional-certification organizations
Pharmacies
Insurance companies
Media networks
Technology platforms
Political officials
Financial institutions
Each institution appeared to act independently.
Yet their decisions repeatedly moved in the same direction.
Vaccines received extraordinary funding, accelerated development, institutional protection and global promotion.
Inexpensive disputed treatments received ridicule, delayed research, prescription barriers and professional hostility.
Whether this alignment resulted from deliberate coordination, shared financial interests, bureaucratic conformity or institutional self-protection is one of the questions the coming investigation will examine.
When Material Becomes the Highest Love
The investigation eventually reaches beyond medicine.
Why does society go to war?
The answer is presented through the language of freedom, security and national honor.
But soldiers surrender their bodies while industries receive contracts, institutions acquire power and corporations gain access to resources and markets.
The same contradiction appears in healthcare.
The patient is presented as the purpose.
But the patient may become the product.
A healthy person who requires little continuing treatment produces limited revenue.
A chronically managed patient can remain profitable for decades.
An inexpensive medicine that works exceptionally well may create a satisfied patient.
A collection of incomplete remedies creates a returning customer.
When material wealth becomes humanity’s highest love, the system does not necessarily reward what heals most completely.
It rewards what can be owned, patented, prescribed repeatedly and sold continuously.
The Upcoming Investigation
The next Red Blood Journal series will examine:
Part I — When Healing Threatens the Market
The disappearance of original Comtrex and the medicine cabinet that replaced it.
Part II — The Risks We Are Allowed to Take
Why society accepts enormous risks from profitable products while denying informed medical choice over much smaller ones.
Part III — Roundup and the Price of Protection
Non-Hodgkin lymphoma, corporate power, litigation and the products considered too materially important to remove.
Part IV — Medicine Under Permission
How licensing boards, hospitals, pharmacies and professional organizations can override the doctor–patient relationship.
Part V — The Horse-Pill Campaign
Ivermectin, the Zelenko protocol, media ridicule and the difference between legal access and practical availability.
Part VI — When Material Becomes the Highest Love
The final connection between medicine, war, institutional power and the material system that quietly places profit above human life.
A Warning Before the Investigation Begins
This series will not claim that every forbidden medicine works.
It will not claim that every approved treatment is fraudulent.
It will not replace one form of blind obedience with another.
It will do something more dangerous.
It will compare the explanations.
It will measure whether the risks were treated consistently.
It will follow the money.
It will examine who benefited.
It will ask why some products received protection while others received elimination.
It will distinguish scientific uncertainty from institutional certainty.
And it will preserve the testimony of people who remember what happened before the historical record was rewritten into something cleaner, safer and easier to defend.
The question is no longer merely whether Comtrex worked.
The question is:
Who possesses the authority to decide what may heal us—and what material interests are protected when that choice is taken away?
The investigation begins next.
Do not expect it to remain inside the medicine cabinet.
🩸 RedBloodJournal.com 🩸
From the ocean of love and positivity—
where human life must always remain more valuable than the material systems created to serve it.
🩸🌊✨ Fantastic!
🩸 The Red Blood Journal:
Who Controls Healing?
Jul 17, 2026
The Red Blood Journal presents a critical analysis of the imbalances within modern healthcare and the influence of corporate power over medical freedom. The text argues that institutional gatekeepers often prioritize profitable, patented products over inexpensive or highly effective treatments, citing the removal of the original Comtrex formula as a primary example. By comparing the legal protection of high-risk industrial chemicals to the suppression of certain medicines, the author highlights a double standard in how society permits personal risk. The narrative further explores how professional intimidation and media campaigns were used to restrict doctors’ autonomy during the pandemic. Ultimately, the source suggests that the current medical system favors chronic management over total healing because material wealth has become the primary driver of institutional decision-making.
